Properties of Ro 13-9904 as a Substrate and Inhibitor of %beta;-Lactamases
- 2 January 1981
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 27 (1), 25-31
- https://doi.org/10.1159/000238025
Abstract
Ro 13-9904 is a novel semisynthetic and highly active parenteral cephalosporin. Its stability against hydrolysis by several β-lactamases was studied. The enzymes were isolated from various Enterobacteriaceae or Staphylococcus aureus and several commercially available enzyme preparations were also included. Most of the penicillinases, cephalosporinases or the TEM-type β-lactamase studied were unable to hydrolyze this novel cephalosporin. The cephalosporinases from Bacillus cereus 569/H9 and Proteus vulgaris 1028, however, were found to readily cleave all new cephalosporins like cefuroxime, cefotaxime and Ro 13-9904, but not cefoxitin. Ro 13-9904 was seen to be a potent inhibitor of several cephalosporinases, but had little or no affinity for penicillinases or the TEM lactamase.Keywords
This publication has 5 references indexed in Scilit:
- Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studiesAntimicrobial Agents and Chemotherapy, 1980
- Purification and properties of a new beta-lactamase from Pseudomonas cepaciaAntimicrobial Agents and Chemotherapy, 1980
- Outer-Membrane Penetration Barriers as Components of Intrinsic Resistance to Beta-Lactam and Other Antibiotics in Escherichia coli K-12Antimicrobial Agents and Chemotherapy, 1979
- Lack of Correlation Between β-Lactamase Production and Susceptibility to Cefamandole or Cefoxitin Among Spontaneous Mutants of EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 1979
- Iodometric Assay Method for Beta-Lactamase with Various Beta-Lactam Antibiotics as SubstratesAntimicrobial Agents and Chemotherapy, 1978